SNTI — Senti Biosciences Income Statement
0.000.00%
- $11.16m
- -$12.46m
- $2.56m
- 19
- 36
- 20
- 14
Annual income statement for Senti Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.085 | 0.566 | 2.76 | 4.29 | 2.56 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 21.9 | 25.5 | 43.2 | 65.1 | 95.3 |
Operating Profit | -21.8 | -24.9 | -40.5 | -60.8 | -92.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -21.2 | -19.9 | -55.3 | -49.7 | -83.4 |
Net Income After Taxes | -21.2 | -19.9 | -55.3 | -49.7 | -83.4 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -21.2 | -19.9 | -55.3 | -58.2 | -71.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -21.2 | -19.9 | -55.3 | -58.2 | -71.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.84 | -4.5 | -12.7 | -11.6 | -12.9 |
Dividends per Share |